These findings demonstrate that TTC36 specifically enables compensatory hyperactivation of the PI3K/Akt pathway in response to growth factor stimulation, providing a potential mechanism for TTC36-induced sorafenib resistance in HCC. Here, AKT1 is linked to hepatocellular carcinoma.